Tuesday, December 7, 2010

Guidance for Industry: Use of Serological Tests To Reduce the Risk ofTransmission of Trypanosoma cruzi Infection in Whole Blood and BloodComponents Intended for Transfusion; Availability.

Free Diet Profile 468x60

ArabicChinese (Simplified)Chinese (Traditional)DeutchEspanolFrenchItalianJapaneseKoreanPortugueseRussian

FDA is announcing the availability of a document entitled "Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components Intended for Transfusion" dated December 2010. The guidance document notifies establishments that manufacture whole blood and blood components intended for transfusion about FDA license approvals for serological test systems for the detection of antibodies to T. cruzi. These tests are intended for use as donor screening tests to reduce the risk of transmission of T. cruzi infection by detecting antibodies to T. cruzi in plasma and serum samples from individual human donors. The guidance document provides recommendations for one time testing of donations of whole blood and blood components for evidence of T. cruzi infection, blood donor and product management, labeling of whole blood and blood components, and procedures for reporting the implementation of a licensed T. cruzi test. The guidance document does not apply to the collection of source plasma. Also, the guidance does not apply to establishments that make eligibility determinations for donors of HCT/Ps. The recommendations for HCT/P donor screening and testing for T. cruzi antibodies contained in the draft guidance are not being finalized at this time because FDA believes additional consideration of the recommendations is warranted.

At the April 2009 Blood Products Advisory Committee (committee) meeting, FDA sought advice from the committee regarding selective testing strategies for T. cruzi infection in repeat blood donors. After discussing the testing strategies presented, the committee voted in favor of a selective testing strategy in which one negative test would qualify a donor for all future donations without further testing or the need to ask questions regarding risk of a newly acquired T. cruzi infection.

In the Federal Register of March 26, 2009 (74 FR 13211), FDA announced the availability of the draft guidance entitled "Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)" dated March 2009. The guidance announced in this document finalizes only the recommendations concerning testing donations of whole blood and blood components intended for transfusion for T. cruzi antibodies.

At this time, FDA is continuing to review public comments on our recommendations for testing HCT/P donors for T. cruzi. Therefore, we are not finalizing our recommendations for HCT/Ps in this guidance. We intend to issue guidance for testing HCT/P donors for T. cruzi infection in the future.

FDA received numerous comments on the draft guidance and those comments were considered as the guidance was finalized. Editorial changes also were made to improve clarity.

The guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents FDA's current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

This guidance contains information collection provisions that are subject to review by the OMB under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). Elsewhere in this issue of the Federal Register, FDA is publishing a 30-day notice entitled "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components Intended for Transfusion," which announces that the proposed collection of information has been submitted to OMB for review and clearance under the Paperwork Reduction Act. FDA will publish a notice concerning OMB approval of these information collection provisions in the Federal Register prior to the implementation date provided in the guidance document.

The guidance also refers to previously approved collections of information found in FDA regulations. The collections of information in 21 CFR 601.12 have been approved under OMB control number 0910-0338; the collections of information in 21 CFR 606.100, 606.121, 606.122, 606.160(b)(ix), 606.170(b), 610.40, and 630.6 have been approved under OMB control number 0910-0116; the collections of information in 21 CFR 606.171 have been approved under OMB control number 0910-0458.

III. Comments

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) either electronic or written or comments regarding this document. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Source Citation
"Guidance for Industry: Use of Serological Tests To Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components Intended for Transfusion; Availability." Federal Register 6 Dec. 2010. General OneFile. Web. 7 Dec. 2010.
Document URL
http://find.galegroup.com/gps/infomark.do?&contentSet=IAC-Documents&type=retrieve&tabID=T003&prodId=IPS&docId=A243500136&source=gale&srcprod=ITOF&userGroupName=18551_mcpls&version=1.0


Gale Document Number:A243500136

Disclaimer:This information is not a tool for self-diagnosis or a substitute for professional care.

Wal-Mart.com USA, LLCget the best of the bestPersonalized MY M&M'S® Candies(Web-Page) http://applepatchdiet.com/lw17323 Revival Soy: 100% Great Taste Guaranteed(Album / Profile) http://www.facebook.com/album.php?aid=10034&id=1661531726&l=0b77e26203ShopPBS.Org
Email: leonard.wilson2009@hotmail.comShop the Official Coca-Cola Store!
ArabicChinese (Simplified)Chinese (Traditional)DeutchEspanolFrenchItalianJapaneseKoreanPortugueseRussian
Email: leonard.wilson2009@hotmail.com

No comments: